Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kintor to Start US Trial of Baldness Treatment

publication date: Jul 12, 2021

Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Pyrilutamide is a small molecule topical androgen receptor antagonist that inhibits both the androgen receptor and androgen in hair follicle sebaceous glands, thereby treating androgenetic alopecia and acne. The trial is Kintor's fifth US clinical study. Kintor's China Phase II trial of pyrilutamide is nearing its conclusion, with top-line data expected sometime in Q3 of this year. More details....

Stock Symbol: (HK:9939) 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here